Ultragenyx Provides Financial and Business Updates at J.P. Morgan Annual Healthcare Conference
Ultragenyx Pharmaceutical Inc. Preliminary 2025 total revenue of $672 million to $674 million, exceeding top end of guidance Preliminary cash and...
J.P
Celltrion presents innovative drug pipeline and U.S. manufacturing and R&D expansion strategy at the 44th Annual J.P. Morgan Healthcare Conference
Celltrion outlines a blueprint for innovative drug development built on its antibody expertise The company highlights its business strategy to...
30 Years of Foresight: The 2026 J.P. Morgan Long-Term Capital Market Assumptions in Focus
DISCLOSURES The information presented is not intended to be making value judgments on the preferred outcome of any government...
J.P. Morgan Releases 2026 LTCMAs: Sixty-Forty Return 6.4%
This year marks the flagship report's 30th anniversary, showcasing J.P. Morgan's long-standing market expertise and leading research capabilities NEW YORK,...
J.P. Morgan Releases 2026 Long-Term Capital Market Assumptions, Highlighting Resilient 60/40 Portfolios and Opportunities to Enhance Diversification in a New Era of Economic Nationalism and AI Advancement
This year marks the flagship report's 30th anniversary, showcasing J.P. Morgan's long-standing market expertise and leading research capabilities NEW YORK,...
Introducing the 29th Edition of J.P. Morgan Asset Management’s Long-Term Capital Market Assumptions
DISCLOSURES The information presented is not intended to be making value judgments on the preferred outcome of any government...
